Lampidis News

Lampidis News

Promising Results Bode Well For 2014


Despite reduced resources in 2014, we continue to be productive here at the Lampidis Cancer Research Lab at UM.

From in vitro to in vivo results and now completion of a Phase I trial, we have demonstrated that 2-deoxyglucose (2-DG) is able to kill the most resistant cancer cell populations found within every solid tumor, regardless of its type.

Our research this coming year will be focused on investigating how and why 2-DG can best be delivered and applied in combination with other therapeutic drugs. Mechanisms by which metabolic pathways can be targeted simultaneously to yield maximal anti-tumor effects with specific emphasis on energy as well as ER stress will be studied. And we have obtained some encouraging preliminary results: Alzet pump low-dose continuous delivery of 2-DG (below an insulin-inducing response) appears to be effective in reducing tumor growth. We have identified combinations with 2-DG and non-chemotherapeutic agents that are highly effective in vivo in controlling human melanoma cell growth.

With your support, we can accelerate our efforts to bring this universal treatment to cancer patients worldwide.

Here’s a selection of our recently published papers:

Targeting cisplatin-resistant human tumor cells with metabolic inhibitors. Sullivan EJ, Kurtoglu M, Brenneman R, Liu H, Lampidis TJ. Cancer Chemother Pharmacol. 2013 Dec 19. [Epub ahead of print]. View Article

Increased sensitivity to glucose starvation correlates with downregulation of glycogen phosphorylase isoform PYGB in tumor cell lines resistant to 2-deoxy-D-glucose. Philips KB, Kurtoglu M, Leung HJ, Liu H, Gao N, Lehrman MA, Murray TG, Lampidis TJ. Cancer Chemother Pharmacol. 2013 Dec 1. [Epub ahead of print]. View Article

Conversion of 2-deoxyglucose-induced growth inhibition to cell death in normoxic tumor cells. Liu H, Kurtoglu M, Cao Y, Xi H, Kumar R, Axten JM, Lampidis TJ. Cancer Chemother Pharmacol. 2013 Jul;72(1):251-62. doi: 10.1007/s00280-013-2193-y. Epub 2013 May 23. View Article

Endoplasmic reticulum stress induced by 2-deoxyglucose but not glucose starvation activates AMPK through CaMKKβ leading to autophagy. Xi H, Barredo JC, Merchan JR, Lampidis TJ. Biochem Pharmacol. 2013 May 15;85 (10):1463-77. doi: 10.1016/j.bcp.2013.02.037. Epub 2013 Mar 13. View Article

Models and discovery strategies for new therapies of retinoblastoma. Houston SK, Lampidis TJ, Murray TG. Expert Opin Drug Discov. 2013 Apr; 8(4):383-94. doi: 10.1517/17460441.2013.772975. Epub 2013 Feb 22. Review. View Article

read more
Lampidis News

Why your support is so vital


One question we get asked a lot is “Why is your Foundation different from any other cancer foundation that funds cancer research?” A reasonable question from any potential donor, and one I asked myself before committing to the cause.

Over the past year I have learned a lot about cancer and cancer treatments, and as a layman tried to educate myself about the science behind Dr. Lampidis’ groundbreaking research. One key factor that attracted me and made me become an advocate for his work was the elegant simplicity of his science. He uses a false sugar called 2-DG to literally starve tumor cells which rely on glucose to survive in a non-oxygen (hypoxic) environment. This process (glycolysis) is so fundamental, it has survived a billion years of evolution dating back to a time when there was no oxygen in our atmosphere and the only source of energy that could be used to sustain life was sugar.

Combined with the fact that unlike other treatments that are limited to certain cancers, Dr Lampidis offers a universal approach to treating all types of cancer – and we are on the brink of something that could benefit mankind immeasurably.

So why aren’t pharmaceutical companies jumping all over this research to be first to market with a 2-DG wonder drug, you might reasonably ask? The unfortunate reality is that since this analog of glucose cannot be patented, drug companies are not financially motivated to devote their resources to help us develop it for further clinical trials. And although Dr. Lampidis has received almost continuous funding from the government in the form of National Cancer Institutes of Health Awards to investigate how and why 2-DG can best be delivered and applied in combination with other therapeutic drugs, due to dwindling federal resources, he must turn to philanthropy to keep his vital research moving forward.

Cancer is something that affects us all – whether personally or through someone who is close. As I approach the anniversary of the death of my best friend to this devastating disease this week, our efforts to bring this universal treatment to the world take on added relevance and poignancy for me personally. But whatever your motivation, if you’re looking for reasons to support us, given the far-reaching implications of Dr. Lampidis’ work the opportunity to be a part of this global legacy is hopefully reason enough.

read more
Lampidis News

Microteatro Miami Supports Lampidis Cancer Foundation


Actress Lorena Rojas and Uno Magnetic are supporting the Lampidis Cancer Foundation through a series of plays at this month’s Microteatro event in Miami.

WHERE: Micro Theater Miami, Centro Cultura Español, 1490 Biscayne Boulevard in Miami, Florida.

WHEN: October 10 – November 10, 2013. The red carpet launch event, hosted by Lorena Rojas, will be held October 10th from 8-12pm.

WHAT: Series of unique plays, performed in shipping containers, written and produced by Latino writers and directors and acted by well-known Latina actresses such as Lorena Rojas. Please visit for dates and times.

ON VIEW: The opening night gala event will be a red carpet affair hosted by famed actress, singer, and songwriter Lorena Rojas. Also in attendance will be Dr Theodore Lampidis, founder and principal investigator of the Lampidis Cancer Foundation and Mark Osenga CEO of UNO Magnetic. All will be available for photographs and video interviews. Guests of the launch event can purchase UNO Magnetic jewelry at a special table at the entrance with 100% of net proceeds benefitting the Lampidis Cancer Foundation. For those who wear their UNO Magnetic jewelry during the event, they will receive complementary happy hour refreshments. Artist G. Fajardo will be at the event using her skills to paint a special canvas that when completed will spell out “Attract a Cure”. UNO Magnetic jewelry will also be sold on-site during the month of the series. For more information on UNO Magnetic, go to For more information on the Lampidis Cancer Foundation, go to We hope you are able to attend if in town. Thanks to all who have helped put this event together.

read more
Lampidis News

Explotación de un Rasgo Universal del Cáncer


La Escuela de Medicina Leonard M. Miller de la Universidad de Miami es un centro principal de las investigaciones del cáncer, y Theodore Lampidis, PhD es una de sus estrellas. El Dr Lampidis ha consagrado su carrera científica a entender las complejidades de la biología de las células tumorales y de los mecanismos mediante los cuales los cánceres se vuelven resistentes al tratamiento. Sus años de escrupuloso trabajo han dado frutos; descubrió una manera de eliminar selectivamente las poblaciones de células cancerosas más resistentes al tratamiento que se encuentran en todos los tumores sólidos: las células de crecimiento lento.

Significado: El cáncer es una de las enfermedades más devastadoras, y es responsable del fallecimiento de millones de personas al año en todo el mundo. Solamente en Estados Unidos, 550,000 personas fallecen cada año debido a esta enfermedad.

Antecedentes: La quimioterapia y la radiación del cáncer atacan la maquinaria de división de las células, y por lo tanto sólo afectan las células de división rápida.

Problema: Además de las células de crecimiento rápido, los tumores sólidos también contienen células de crecimiento lento. Por lo tanto, las células cancerosas de crecimiento lento que se encuentran en el centro de cada tumor sólido permanecen inalteradas, resistentes a la quimioterapia. Esto da como resultado que después del tratamiento las células exteriores de crecimiento rápido se vuelvan a multiplicar. Más aún, como estas células cancerosas sobreviven un entorno hostil de bajas concentraciones de oxígeno (hipoxia), se han identificado como aquellas que ocasionan las metástasis.

Solución: El hecho de que estas células de crecimiento lento se encuentran en condiciones de hipoxia es clave para este descubrimiento de cómo destruirlas selectivamente. Bajo hipoxia, la supervivencia de las células tumorales depende de la glucosa como su única fuente de energía. Con el uso de una glucosa falsa, la 2-desoxiglucosa (2-DG), el Dr Lampidis ha podido demostrar que al bloquear esta única fuente de energía, las células cancerosas hipóxicas de lento crecimiento y resistentes a la quimioterapia literalmente ¡“se mueren de hambre”! El Dr Lampidis describe los principios bioquímicos sobre los cuales basa su trabajo como: “tan fundamentales como la gravedad”.

Su descubrimiento debe tener implicaciones profundas en la terapia del cáncer, ya que ahora proporciona un medio para atacar todo el tumor al eliminar selectivamente la población de células tumorales de crecimiento lento que se encuentra en todos los tumores sólidos.

En contraste, como nuestras células normales reciben oxígeno y pueden usar otras fuentes de carbono para su supervivencia, como grasas y proteínas, cuando se las trata con 2-DG no resultan afectadas por este tratamiento. De manera muy similar a la dieta Atkins, si se eliminan los carbohidratos como fuente de energía, el organismo quema las grasas y las proteínas, siempre que haya oxígeno.

Un proceso fundamental: El Dr Lampidis está trabajando en un proceso metabólico (glicólisis) que data desde hace más de mil millones de años, cuando no había oxígeno en la atmósfera y pequeños microbios dependían del uso de azúcares como único medio de supervivencia. La glicólisis proviene del griego “glico” que significa dulce y de “lisis” que significa descomposición, y describe la ruta mediante la cual se metaboliza la glucosa. Un proceso tan fundamental, que ha sobrevivido mil millones de años de evolución, se encuentra en el corazón de su descubrimiento.

Progreso y estado actual de su investigación: Los resultados de sus estudios in vitro e in vivo lograron la aprobación de la FDA para realizar un estudio clínico de fase I, en el que se usó la 2-DG en combinación con Taxotere (un medicamento quimioterapéutico estándar que ataca solamente células tumorales de rápido crecimiento). Los resultados de este estudio (recientemente publicado) mostraron que la 2-DG es bien tolerada, y establece la base para estudios de fase II y ulteriores.

Más aún, en colaboración con el Dr Timothy Murray, un experto internacional en la investigación y el tratamiento de niños con retinoblastoma (un cáncer que afecta los ojos) han proporcionado pruebas del principio de que la 2-DG mata las células cancerosas hipóxicas de este tumor. Demostraron que junto con carboplatino, un agente quimioterapéutico, la 2-DG restablece el epitelio retinal normal que se requiere para ver. El Dr Murray ha dicho “la 2-DG puede ser lo mejor que ha surgido para esta enfermedad en los últimos 10 años”.

Necesidad de apoyo filantrópico: El Dr Murray y sus asociados están listos para emprender un estudio clínico piloto de fase I/II de pacientes con retinoblastoma, y estudios de fase II en una variedad de tipos de cáncer. El Dr Murray ha recibido numerosas indagaciones de pacientes y médicos que desean saber dónde pueden recibir tratamiento con 2-DG para sus diferentes tipos de cáncer. Sin embargo, como la 2-DG no se puede patentar, las compañías farmacéuticas no pueden proporcionar los fondos necesarios para estudiar la 2-DG en estudios clínicos, lo que se requiere para que finalmente sea usada como tratamiento universal contra el cáncer. Por lo tanto, los estudios clínicos no pueden proceder sino hasta que los fondos estén seguros.

Aunque durante los últimos 32 años el Dr Lampidis ha tenido un récord excepcional de financiamiento casi continuo del Instituto Nacional del Cáncer (National Cancer Institute) de los Institutos Nacionales de Salud (National Institutes of Health), lamentablemente debido a los menguantes fondos federales ya no puede depender del gobierno para continuar el progreso de su investigación. Además, su trabajo ha alcanzado un punto en el que se requieren más fondos para pasar su tecnología del laboratorio a la clínica.

El costo de un solo estudio clínico, que ayudaría a acercar el uso de la 2-DG por los pacientes es más de 2 o 3 millones de dólares. Para que finalmente la usen los pacientes (a través de más estudios clínicos) se requerirán aproximadamente 10 a 15 millones de dólares más. El costo requerido para mantener el trabajo investigativo de laboratorio para realizar más estudios clínicos se encuentra en el rango de 3 millones de dólares por el periodo de los próximos cinco años. Por esto, estamos iniciando una campaña para recaudar 20 millones de dólares.

Al igual que con las iniciativas más importantes, se requieren los esfuerzos colectivos de un grupo diverso de personas (no sólo el creador) para llevar una idea médica hasta el uso clínico real, debido a que hay tantos obstáculos a vencer. El Dr Lampidis y sus colegas de la investigación se encuentran a punto de lograr varios avances importantes, pero sin los fondos necesarios para apoyar esta vital investigación, el logro del uso clínico es poco realista.

Si le interesa ayudar a lograr que esta innovadora investigación pase por estudios clínicos apropiados a fin de que se pueda usar para ayudar a salvar vidas, por favor envíe sus donativos a la siguiente dirección especificando lo siguiente:

Por favor haga su donativo pagadero a: Lampidis Cancer Foundation

Envíelo a: Lampidis Cancer Foundation, 16404 SW 86 Court, Miami FL 33157, USA

Todos los donativos son deducibles de impuestos, y cada donador recibirá una confirmación de agradecimiento por escrito de parte de Lampidis Cancer Foundation que se puede usar para propósitos impositivos.

Información sobre los antecedentes del Dr Theodore J. Lampidis: El Dr Lampidis se graduó en Brooklyn College con un grado de licenciatura en ciencias, con especialización en química, y recibió su grado de maestría en microbiología médica en la Universidad de Nueva York. Recibió su PhD en inmunología y microbiología de la Universidad de Miami, y completó su capacitación postdoctoral en la División de Oncología del Departamento de Medicina de la Escuela de Medicina de Harvard. En 1983 regresó a Miami y se integró al Departamento de Oncología de Sylvester Comprehensive Cancer Center en UM como profesor asistente, y en 1995 obtuvo el grado de profesor titular.

El Dr Lampidis continúa siendo un líder mundial en investigaciones sobre el cáncer y la 2-DG. Ha publicado más de 100 artículos de investigación. Tiene un récord excepcional de financiamiento casi continuo de NIH/NCI para su trabajo en cáncer, y ha sido ponente invitado en muchos institutos de cáncer de prestigio en todo el mundo, entre ellos: Oxford University en Oxford, Inglaterra; Max Planck Institute en Munich, Alemania; The Paul Brousse Institute en Villejuif, Francia; The Royal Marsden Hospital en Londres, Inglaterra; The Harvard Medical School en Boston, Massachusetts; The Albert Einstein Cancer Center y The Sloan Kettering Cancer Center en NYC, NY; The MD Anderson Cancer Center en Houston, Texas y muchos otros. Su trabajo en UM ha pasado del laboratorio a la clínica, dando como resultado estudios clínicos de fase I y de fase II iniciados por el investigador.

read more
Lampidis News

Uno Magnetic Partners with Latina Celebrity Lorena Rojas and the Lampidis Cancer Foundation


The Lampidis Cancer Foundation has partnered with interactive lifestyle company Uno Magnetic and famed Latina celebrity Lorena Rojas to raise awareness and funding for the groundbreaking cancer research of Dr Theodore Lampidis.

Founded by the award-winning designer Luis Pons, Uno Magnetic will support the Foundation through the sale of their innovative range of interactive bracelets. A special landing page on features the work of Dr Lampidis and showcases the products available for purchase. The bracelets retail for between $10-$14 per item and 100% of the net proceeds from the sale of each bracelet will go to the Foundation.

The partnership is supported by Lorena Rojas, a Mexican actress, singer, and song writer who is best known for her leading roles in popular Telenovelas. A cancer sufferer herself, Ms Rojas is a keen supporter of the potentially life-changing work of Dr Lampidis and is helping to raise awareness among her considerable fan base.

Dr Lampidis is the Professor of Cell Biology at the University of Miami and a member of Sylvester Comprehensive Cancer Center. He is a pioneer in exploring and exploiting the unique usage of glucose in cancer cells using simple sugars such as 2-Deoxyglucose (2-DG) to kill tumors. His discovery is based on the fact that the cancer cells most resistant to chemotherapy found within the inner core of all solid tumors do not receive enough oxygen (hypoxia) and therefore must rely exclusively on sugar to survive. Feeding these hypoxic tumor cells a false sugar such as 2-DG effectively ‘starves’ them to death.

Unfortunately, 2-DG is not patentable and so pharmaceutical companies are not interested in investing in future clinical trials. Hence, the Lampidis Cancer Foundation has been campaigning to raise $10 million to support Dr Lampidis’ pioneering work on 2-DG through the next stages of clinical trials, with the single-minded goal of making it readily available to cancer sufferers around the world.

According to Lorena Rojas, “As a cancer sufferer myself, I am only too acutely aware of the effect this disease can have on people. But now, thanks to Dr Theodore Lampidis’ groundbreaking research, there is hope for millions of people like me who are affected by this devastating global disease.”

Mark Osenga, CEO of Uno Magnetic, said, “Thanks to Dr Lampidis’ remarkable work, we could be on the brink of a cure for cancer, and hopefully the sale of Uno bracelets will help to ensure that his research is brought to fruition for the benefit of Lorena and millions of people like her.”

“We are extremely grateful to Lorena and Uno Magnetic for supporting our fundraising endeavors,” said Lee Phillips, Executive Director at the Lampidis Cancer Foundation. “This unique collaboration will hopefully help us accelerate Phase 2 clinical trials for 2-DG and make this potential cure readily available to cancer sufferers around the world.”

For further information on Uno Magnetic visit

For further information on the Lampidis Cancer Foundation visit

read more
Lampidis News

Potential Application of 2-DG to Block Herpes Virus

no thumb

In collaboration with Dr. Enrique Mesri, an expert in herpes virus replication and the mechanism by which this virus drives the most prevalent cancer found in AIDS patients (Kaposi’s sarcoma), we have recently reported that 2-DG has remarkable effects in blocking viral formation in three different strains of herpes. Our findings offer the possibility of not only developing a new way to stop herpes virus multiplication, but this protocol may extend to other viruses such as influenza, Hepatitis C, and even the virus that causes AIDS itself, HIV, as well as many others.

Similar to what we previously reported in cancer cells growing under normal oxygen conditions, our data shows that 2-DG interferes with the process by which sugars are added onto proteins (n-linked glycosylation) that are critical for the functioning of tumor cells as well as viruses. These results further indicate the wide-reaching and extraordinary role that 2-DG is just now beginning to gain recognition for, as both an anti-cancer as well as an anti-viral agent. Although much work remains to be done to bring 2-DG to clinical application in both of these global diseases, our findings in Phase I trials where 2-DG was found to be well-tolerated by cancer patients treated over extended periods offer much hope that these goals can realistically be achieved.

read more
Lampidis News

Global Interest in Clinical Application of 2-DG Growing


Since we started our journey in the late 1990s using the sugar analogue 2-DG to target the hypoxic population of cells found in solid tumors, there has been increasing interest in this compound as witnessed by the number of labs and publications studying it. Having published the results of our completed Phase I trials this year (see link below) we have received several inquiries from research scientists around the world including Japan, Spain and others inquiring about 2-DG’s availability for further clinical testing. As a result of the growing realization of the importance of 2-DG for probing and exploiting increased glucose metabolism in cancer, we continue to initiate global collaborations. With the essential input of philanthropic support our goal is to become a resource that physicians and scientists can use to obtain clinical grade 2-DG, as well as share information and findings on how best to use it as a single agent and in combination with standard cancer chemotherapeutic or non-chemotherapeutic agents. Attaining this goal should have a significant impact in the treatment of most types of cancer, and with your help, we will make it happen.

Research Publication: A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors. Raez LE, Papadopoulos K, Ricart AD, Chiorean EG, Dipaola RS, Stein MN, Rocha Lima CM, Schlesselman JJ, Tolba K, Langmuir VK, Kroll S, Jung DT, Kurtoglu M, Rosenblatt J, Lampidis TJ. Cancer Chemother Pharmacol. 2012 Dec 11

read more
Lampidis NewsMedical Research

Using a False Sugar to Kill Cancer


At the heart of Dr Lampidis’ groundbreaking cancer research is a process so fundamental that it has survived a billion years of evolution. This process, termed glycolysis originating from Greek “glyco” meaning sweet and “lysis” meaning breakdown, evolved as the only means by which tiny microbes could survive at a time when there was no oxygen in our atmosphere.

There are three basic energy sources from which humans derive energy – carbohydrates, fats and proteins – but without oxygen, only sugar (a form of carbohydrate) can be used to sustain life.

The most difficult cancer cells to successfully treat are found in the center of a tumor where there is little or no oxygen, a condition known as hypoxia (see figure below). These hypoxic cancer cells are not only resistant to chemotherapy and radiation but also give rise to metastases (spreading of the cancer from the original site to other parts of the body). Dr Lampidis reasoned that because they depend on sugar to exist (similar to the microbes of a billion years ago), he could selectively kill these hypoxic cancer cells by blocking glycolysis with a false sugar, 2-deoxyglucose (2-DG).

He proved his idea in cancer cells growing under hypoxic conditions in a petri dish and from there in laboratory animals where the tumors naturally contain hypoxic cells. With the outstanding help of several physicians his idea was brought to reality with the completion of an FDA approved Phase I trial in humans.

Unfortunately, 2-DG is not patentable and so pharmaceutical companies are not interested in investing in future clinical trials. Hence the Lampidis Cancer Foundation has been campaigning to raise funds to support Dr Lampidis’ pioneering work on 2-DG through the next stages of clinical trials, with the single-minded goal of making it readily available to cancer sufferers around the world.

read more
Lampidis News

On the Brink of a Universal Treatment for Cancer


Theodore Lampidis, Ph.D., Professor in the Department of Cell Biology and a member of Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, is a pioneer in the exploration of the intricate metabolism of glucose in cancer cells and the discovery of how to exploit this process by using simple sugars such as 2-Deoxyglucose (2-DG).

Background: Dr. Lampidis’ groundbreaking cancer research is founded on the following facts: Solid tumors (carcinomas) consist of an outer shell of fast-growing cells and an inner core of slow-growing cells. Although standard chemotherapy attacks the fast-dividing cells, it cannot distinguish between normal and cancerous cells. That is why cancer patients treated with chemotherapy lose their hair, suffer low blood counts, and experience diarrhea and vomiting. Those are the normal tissues in the body that contain the rapidly dividing cells.

The Problem: Since chemotherapy works by interfering with the dividing machinery of cells, it cannot effectively eliminate the slow-growing cells found within the inner core of all solid tumors. It is these slow-growing cancer cells which contribute to the regrowth of the outer cells after treatment. Most importantly, these inner core tumor cells are responsible for metastasis which leads to the spread of the tumor to various parts of the body. Fortunately, however, slow-growing tumor cells have inadequate blood supplies and thus low oxygen (hypoxia). This means they must use much more sugar than normal cells to provide the energy they need to survive, a process known as glycolysis.

The Solution: Dr. Lampidis hypothesized he could “trick” these hypoxic tumor cells by feeding them “false” sugars, such as 2-DG (2-deoxyglucose), to keep them from metabolizing the actual sugar they need to survive. Because they do not have the necessary oxygen to use fats and proteins as alternative sources of energy, they would literally “starve to death.” Meanwhile, the normal cells would survive because they do metabolize these alternate sources (think about the Atkins Diet – when you lower your intake of carbohydrates [sugars] you burn fats and proteins instead).

Success to date: Dr Lampidis’ eureka moment led to two consecutive five-year awards from the National Cancer Institute, which stated in the reviews of his research that “Dr. Lampidis’ work could eventually lead to cures in certain cancers.” Based on his work, an FDA approved Phase I clinical trial was conducted to determine the tolerable dose level of 2-DG. Before they progress to a Phase II clinical trial, further work is required to investigate and develop the most efficient drug delivery method, eg: slow release pump, pill or diet. In addition, working in collaboration with Dr. Tim Murray, a leading expert in the investigation and treatment of children with eye cancer (retinoblastoma) formally at the Bascom Palmer Eye Institute, Dr. Lampidis and his colleagues have demonstrated that 2-DG raises the efficacy of the chemotherapeutic agent (carboplatin) used to treat this disease. Moreover, using pimonidazole, which identifies hypoxic tumor cells, they have provided the first proof of principle that indeed 2-DG, but not carboplatin, targets and kills the hypoxic portion of this tumor. Based on these very encouraging in vivo results, they plan to begin a pilot Phase I trial in patients whose eyes cannot be saved by current treatments.

Dr Theodore Lampidis: “I am convinced that the biochemical principles at the heart of our work are as fundamental as gravity. That is why I believe investigating tumor metabolism in general and glucose metabolism in particular, will lead to significant and real advances in the struggle we all one way or another face in fighting this devastating disease.”

We need your help: Our mission at the Lampidis Cancer Foundation is to bring the groundbreaking research of Dr. Theodore Lampidis through the clinical trial and testing phase so that this treatment protocol can begin to help those suffering from various types of cancer. If you are interested in supporting this vital work or would like to find out more, please visit or call us on +1.305.243.4846.

read more
Lampidis News

WorldPay Sponsors the Lampidis Cancer Foundation


The Lampidis Cancer Foundation has partnered with global payment processing company WorldPay to raise awareness and funding for the work of Dr Theodore Lampidis among the business community. Switch to WorldPay as your electronic payment processing provider and WorldPay will donate a portion of their profit to the Lampidis Cancer Foundation on your behalf to help fund groundbreaking efforts in cancer research.

Dr Lampidis is the Professor of Cell Biology at the University of Miami and a member of Sylvester Comprehensive Cancer Center. He is a pioneer in exploring and exploiting the unique usage of glucose in cancer cells using simple sugars such as 2-Deoxyglucose (2-DG). His discovery is based on the fact that the cancer cells most resistant to chemotherapy found within the inner core of all solid tumors do not receive enough oxygen (hypoxia) and therefore must rely exclusively on sugar to survive. Feeding these hypoxic tumor cells a false sugar such as 2-DG effectively ‘starves’ them to death and kills off the tumor.

Unfortunately, 2-DG is not patentable and so pharmaceutical companies are not interested in investing in future clinical trials. With recent cuts to Federal funding, the Lampidis Cancer Foundation has been campaigning to raise $10 million to support Dr Lampidis’ pioneering work on 2-DG through the next stages of clinical trials, with the single-minded goal of making it readily available to cancer sufferers around the world.

WorldPay processes payments for more than 500,000 businesses around the world, from name brand retailers to your favorite local shop. According to Mark Phillips, regional account executive for WorldPay in Florida, “We are delighted to be able to support the potentially life-changing work of Dr Lampidis. This partnership offers an easy way for participating businesses and their customers to support such a worthy cause.”

“We are extremely grateful to WorldPay for supporting our fundraising endeavors,” said Lee Phillips, Executive Director at the Lampidis Cancer Foundation. “Their global reach and trusted brand will be invaluable to us in raising awareness of Dr Lampidis’ vital cancer research among the business community, and will help us accelerate Phase 2 clinical trials for 2-DG.”

To find out more how you can become a WorldPay partner and support the Lampidis Cancer Foundation, visit:

read more